NASDAQ:ELUT Elutia (ELUT) Stock Price, News & Analysis → Conflict In Israel Sends Gold Soaring ???? Here’s How To Get Your Share (From Colonial Metals) (Ad) Free ELUT Stock Alerts $2.93 +0.15 (+5.40%) (As of 04/29/2024 ET) Add Compare Share Share Today's Range$2.77▼$2.9950-Day Range$2.78▼$3.7052-Week Range$1.10▼$4.19Volume27,848 shsAverage Volume7,652 shsMarket Capitalization$71.11 millionP/E RatioN/ADividend YieldN/APrice Target$6.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media Get Elutia alerts: Email Address Elutia MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside104.8% Upside$6.00 Price TargetShort InterestHealthy0.19% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment-0.33Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.07 out of 5 starsMedical Sector574th out of 920 stocksBiological Products, Except Diagnostic Industry94th out of 155 stocks 3.5 Analyst's Opinion Consensus RatingElutia has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageElutia has received no research coverage in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted0.19% of the float of Elutia has been sold short.Short Interest Ratio / Days to CoverElutia has a short interest ratio ("days to cover") of 1.5, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Elutia has recently increased by 39.41%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldElutia does not currently pay a dividend.Dividend GrowthElutia does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ELUT. Previous Next 0.9 News and Social Media Coverage News SentimentElutia has a news sentiment score of -0.33. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.34 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Elutia this week, compared to 1 article on an average week. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Elutia insiders have not sold or bought any company stock.Percentage Held by Insiders37.10% of the stock of Elutia is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions74.03% of the stock of Elutia is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Elutia is -1.39, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Elutia is -1.39, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad The Bull ReportHealthcare Takes A Big Step Forward With The Help Of AIThe average doctor can diagnose an illness correctly 50-90% of the time. But one innovative company's medical AI gets it right 92%+.Click here to see why this small company is trusted by the Mayo Clinic About Elutia Stock (NASDAQ:ELUT)Elutia Inc., a commercial-stage company, develops and commercializes drug-eluting biologics products for neurostimulation, wound care, and breast reconstruction in the United States. The company operates in three segments: Device Protection; Women's Health; and Cardiovascular. It offers CanGaroo Envelope, which is used to accommodate cardiac implantable electronic devices, such as pacemakers and internal defibrillators. The company also develops CanGarooRM, a combination of the CanGaroo envelope with antibiotics, to reduce the risk of infection after surgical implantation of an electronic device. In addition, it provides ProxiCor for cardiac tissue repair and pericardial closure; Tyke, an extracellular material that is used in the repair of cardiac structures for neonate and infant patients; and VasCure, a patch material to repair or reconstruct the peripheral vasculature. Further, the company offers SimpliDerm, which uses human acellular dermal matrices for tissue repair and reconstruction in various applications, such as sports medicine, hernia repair, trauma reconstruction, and breast reconstruction surgeries following mastectomy. It serves hospitals and healthcare facilities through its direct sales force, independent sales agents, and distributors. The company was formerly known as Aziyo Biologics, Inc. and changed its name to Elutia Inc. in September 2023. Elutia Inc. was incorporated in 2015 and is headquartered in Silver Spring, Maryland.Read More ELUT Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ELUT Stock News HeadlinesApril 24, 2024 | globenewswire.comElutia to Present at the Planet MicroCap Showcase: VEGAS 2024 on Wednesday, May 1March 10, 2024 | finanznachrichten.deElutia Inc.: Elutia Reports Fourth Quarter and Full Year 2023 Financial Results: Anticipates CanGarooRM Clearance Decision in First Half of 2024April 30, 2024 | Colonial Metals (Ad)Conflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareThe latest flare-up between Israel and Palestinian militants has sent gold prices surging. Why? Because savvy investors know the endgame of the elites at play… Geopolitical crises breed uncertainty — and gold thrives on uncertainty. March 10, 2024 | finance.yahoo.comElutia Full Year 2023 Earnings: Misses ExpectationsMarch 8, 2024 | finance.yahoo.comQ4 2023 Elutia Inc Earnings CallMarch 7, 2024 | investorplace.comELUT Stock Earnings: Elutia Misses EPS, Misses Revenue for Q4 2023March 7, 2024 | benzinga.comRecap: Elutia Q4 EarningsMarch 7, 2024 | globenewswire.comElutia Reports Fourth Quarter and Full Year 2023 Financial Results: Anticipates CanGarooRM® Clearance Decision in First Half of 2024April 30, 2024 | Colonial Metals (Ad)Conflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareThe latest flare-up between Israel and Palestinian militants has sent gold prices surging. Why? Because savvy investors know the endgame of the elites at play… Geopolitical crises breed uncertainty — and gold thrives on uncertainty. March 6, 2024 | benzinga.comPreview: Elutia's EarningsFebruary 22, 2024 | globenewswire.comElutia to Report Fourth Quarter and Full Year 2023 Financial Results on Thursday, March 7, 2024February 22, 2024 | finance.yahoo.comUmoja Biopharma to Participate in a Fireside Chat at the Evercore ISI 2024 Emerging Biotech ConferenceFebruary 21, 2024 | finance.yahoo.comCalliditas Year-end report, January - December 2023February 11, 2024 | wsj.comElutia Inc.February 9, 2024 | proactiveinvestors.comElutia's CanGarooRM: Pioneering Drug-Eluting Biologic for Secure Medical ImplantsFebruary 4, 2024 | msn.comAziyo Biologics Announces Executive Compensation AdjustmentsJanuary 11, 2024 | finanznachrichten.deElutia Inc.: Elutia Regains Compliance with Nasdaq Listing RequirementsJanuary 10, 2024 | msn.comElutia regains compliance with NasdaqJanuary 10, 2024 | finance.yahoo.comElutia Regains Compliance with Nasdaq Listing RequirementsJanuary 10, 2024 | finance.yahoo.comElutia Inc. (ELUT) Stock Historical Prices & Data - Yahoo FinanceJanuary 2, 2024 | bizjournals.comSilver Spring regenerative medicine firm Elutia regains Nasdaq compliance as business prospects brightenDecember 18, 2023 | finance.yahoo.comElutia Submits CanGarooRM® Antibiotic-Eluting Biomatrix for FDA ClearanceNovember 20, 2023 | msn.comElutia files to sell 18.58M shares of Class A common stock for holdersNovember 17, 2023 | msn.comElutia Inc. (ELUT) Upgraded to Buy: Here's WhyNovember 14, 2023 | markets.businessinsider.comWhere Elutia Stands With AnalystsNovember 13, 2023 | benzinga.comElutia: Q3 Earnings InsightsNovember 10, 2023 | benzinga.comEarnings Outlook For ElutiaSee More Headlines Receive ELUT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Elutia and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/07/2024Today4/29/2024Next Earnings (Estimated)5/08/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:ELUT CUSIPN/A CIK1708527 Webwww.elutia.com Phone240-247-1170Fax510-307-9896Employees54Year FoundedN/APrice Target and Rating Average Stock Price Target$6.00 High Stock Price Target$6.00 Low Stock Price Target$6.00 Potential Upside/Downside+104.8%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($2.11) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-37,660,000.00 Net Margins-106.54% Pretax Margin-166.58% Return on EquityN/A Return on Assets-80.27% Debt Debt-to-Equity RatioN/A Current Ratio0.73 Quick Ratio0.64 Sales & Book Value Annual Sales$24.75 million Price / Sales2.87 Cash FlowN/A Price / Cash FlowN/A Book Value($1.66) per share Price / Book-1.77Miscellaneous Outstanding Shares24,273,000Free Float15,268,000Market Cap$71.12 million OptionableNot Optionable Beta0.51 The Best High-Yield Dividend Stocks for 2024Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.Get This Free Report Key ExecutivesDr. C. Randal Mills Ph.D. (Age 52)Co-Founder, President & CEO and Director Comp: $857.26kMr. Matthew B. Ferguson (Age 56)Chief Financial Officer Comp: $360.65kMs. Erica ElchinVice President of Global OperationsDr. Michelle LeRoux Williams Ph.D. (Age 49)Chief Scientific Officer Ms. Courtney GuyerVice President of MarketingDr. Sonali Fonseca Ph.D.VP & Head of Emerging BusinessesMr. Jeffry D. HametSenior VP of Finance, Treasurer & SecretaryMore ExecutivesKey CompetitorsInstil BioNASDAQ:TILPrecision BioSciencesNASDAQ:DTILTurnstone BiologicsNASDAQ:TSBXIkena OncologyNASDAQ:IKNAAthira PharmaNASDAQ:ATHAView All CompetitorsInstitutional OwnershipVerdence Capital Advisors LLCBought 14,410 shares on 4/26/2024Ownership: 0.059%View All Institutional Transactions ELUT Stock Analysis - Frequently Asked Questions Should I buy or sell Elutia stock right now? 2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Elutia in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ELUT shares. View ELUT analyst ratings or view top-rated stocks. What is Elutia's stock price target for 2024? 2 equities research analysts have issued 1 year price targets for Elutia's shares. Their ELUT share price targets range from $6.00 to $6.00. On average, they anticipate the company's stock price to reach $6.00 in the next year. This suggests a possible upside of 104.8% from the stock's current price. View analysts price targets for ELUT or view top-rated stocks among Wall Street analysts. How have ELUT shares performed in 2024? Elutia's stock was trading at $2.16 on January 1st, 2024. Since then, ELUT shares have increased by 35.6% and is now trading at $2.93. View the best growth stocks for 2024 here. Are investors shorting Elutia? Elutia saw a increase in short interest in April. As of April 15th, there was short interest totaling 23,700 shares, an increase of 39.4% from the March 31st total of 17,000 shares. Based on an average daily trading volume, of 16,300 shares, the days-to-cover ratio is currently 1.5 days. Approximately 0.2% of the shares of the company are sold short. View Elutia's Short Interest. When is Elutia's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 8th 2024. View our ELUT earnings forecast. How were Elutia's earnings last quarter? Elutia Inc. (NASDAQ:ELUT) posted its earnings results on Thursday, March, 7th. The company reported ($0.66) earnings per share (EPS) for the quarter. The firm earned $5.88 million during the quarter. Who are Elutia's major shareholders? Elutia's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Verdence Capital Advisors LLC (0.06%). Insiders that own company stock include Birchview Capital, Lp, Brigid Makes, David Colpman, Highcape Capital, LP, Matthew Ferguson, Ronald K Lloyd and Thomas Englese. View institutional ownership trends. How do I buy shares of Elutia? Shares of ELUT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:ELUT) was last updated on 4/30/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsAI finds its first serious applicationWall Street StarForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill PublishingHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportCharles Payne’s Gift to Stock InvestorsUnstoppable ProsperityProtect Your Bank Account Before It’s Too LateWeiss RatingsHe Is Giving Away BitcoinCrypto Swap ProfitsWhy Big Pharma is Investing Billions in This BiotechBehind the Markets Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Elutia Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
